Materialise NV (MTLS)
NASDAQ:MTLS
Want to see MTLS full AI Analyst Report?
MTLS Stock Chart & Stats
$5.46
-$0.59(-7.31%)
At close: 4:00 PM EST
$5.46
-$0.59(-7.31%)
Day’s Range― - ―
52-Week Range$4.78 - $6.80
Previous CloseN/A
Volume181.37K
Average Volume (3M)94.71K
Market Cap
$335.50M
Enterprise Value$211.65M
Total Cash (Recent Filing)$132.95M
Total Debt (Recent Filing)$60.13M
Price to Earnings (P/E)34.6
Beta1.13
Next Earnings
Aug 27, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.18
Shares Outstanding59,067,184
10 Day Avg. Volume143,780
30 Day Avg. Volume94,707
Financial Highlights & Ratios
PEG Ratio-0.87
Price to Book (P/B)1.09
Price to Sales (P/S)1.09
P/FCF Ratio30.53
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue0.76
Enterprise Value/Gross Profit1.32
Enterprise Value/Ebitda6.59
Forecast
1Y Price Target
$9.05Price Target Upside65.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.16
Revenue Forecast (FY)$279.13M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet / Net CashA net cash position and sizable cash reserves provide durable financial flexibility to fund R&D, invest in Medical and Software growth, weather cyclical Manufacturing weakness, and pursue strategic portfolio actions without reliance on volatile external financing.
Medical Segment Growth & Product LaunchesSustained Medical growth and validated product rollouts deepen clinical adoption and create higher‑margin, regulated revenue streams with higher switching costs, supporting long‑term structural growth and profitability resilience versus cyclical industrial end markets.
Recurring Software Revenue And Margin ImprovementA high and growing share of recurring software revenue plus outsized software margin improvement increases revenue visibility and operating leverage, making cash flows more predictable and enabling reinvestment in cloud capabilities and customer retention.
Bears Say
Manufacturing Revenue WeaknessMaterialise's Manufacturing business remains exposed to cyclical prototyping and automotive demand; persistent weakness reduces revenue diversification, pressures segment margins, and requires strategic repositioning toward series production to stabilize long‑term cash generation.
Volatile And Limited Free Cash FlowRelatively small, volatile free cash flow constrains the firm's ability to consistently fund capex, M&A or shareholder returns without drawing on cash reserves; this increases sensitivity to one‑off costs, working capital swings, and investment timing.
Low Returns And Modest ProfitabilityModest net margins and low returns on equity indicate limited current earnings power; absent sustained margin expansion and revenue growth, capital allocation may not generate high shareholder returns, making execution on Medical and Software critical.
Materialise News
MTLS FAQ
What was Materialise NV’s price range in the past 12 months?
Materialise NV lowest stock price was $4.78 and its highest was $6.80 in the past 12 months.
What is Materialise NV’s market cap?
Materialise NV’s market cap is $335.50M.
When is Materialise NV’s upcoming earnings report date?
Materialise NV’s upcoming earnings report date is Aug 27, 2026 which is in 100 days.
How were Materialise NV’s earnings last quarter?
Materialise NV released its earnings results on May 07, 2026. The company reported $0.035 earnings per share for the quarter, beating the consensus estimate of $0.012 by $0.023.
Is Materialise NV overvalued?
According to Wall Street analysts Materialise NV’s price is currently Undervalued.
Does Materialise NV pay dividends?
Materialise NV does not currently pay dividends.
What is Materialise NV’s EPS estimate?
Materialise NV’s EPS estimate is 0.05.
How many shares outstanding does Materialise NV have?
Materialise NV has 59,067,184 shares outstanding.
What happened to Materialise NV’s price movement after its last earnings report?
Materialise NV reported an EPS of $0.035 in its last earnings report, beating expectations of $0.012. Following the earnings report the stock price went down -3.203%.
Which hedge fund is a major shareholder of Materialise NV?
Currently, no hedge funds are holding shares in MTLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Materialise Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.05 (65.75% Upside)
$9.05 (65.75% Upside)
Blogger Sentiment
Bullish
MTLS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 12.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.6%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.66%
12-Months-Change
Fundamentals
Return on Equity
4.11%
Trailing 12-Months
Asset Growth
14.33%
Trailing 12-Months
Company Description
Materialise NV
Materialise NV provides additive manufacturing and medical software, and 3D printing services in the Americas, Europe and Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. Its Materialise Software segment offers software through programs and platforms that enable and enhance the functionality of 3D printers and of 3D printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, Website, and third-party distributors. The company's Materialise Medical segment provides medical software that allows medical-image based analysis and engineering, as well as patient-specific design of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies through its direct sales force, Website, and picture archiving and communication system partners. Its Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to industrial and commercial customers. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.
MTLS Company Deck
MTLS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and financial picture: revenue was stable despite FX headwinds, margins and adjusted profitability improved materially (adjusted EBITDA +>30%, adjusted EBIT up meaningfully), Medical reported solid growth with strategic product launches, software recurring revenue increased and software profitability improved, cash position strengthened, and sustainability and strategic portfolio actions were executed. Offsetting factors include FX-driven reported declines in some areas, an 8% YoY drop in Manufacturing revenue driven by softer prototyping and automotive demand, and the near‑term top‑line impact of divestments. On balance, the favorable profitability trends, cash generation, product and partnership momentum, and reaffirmed guidance outweigh the lowlights.View all MTLS earnings summariesMTLS Stock 12 Month Forecast
Average Price Target
$9.05
▲(65.75% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.11% Mutual Funds
7.44% Other Institutional Investors
91.62% Public Companies and
Individual Investors